BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 15286701)

  • 1. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.
    Nakshatri H; Rice SE; Bhat-Nakshatri P
    Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells.
    Zhang S; Lin ZN; Yang CF; Shi X; Ong CN; Shen HM
    Carcinogenesis; 2004 Nov; 25(11):2191-9. PubMed ID: 15256485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
    Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
    Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX; Ong CN; Shen HM
    Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
    Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
    Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB; Bhardwaj U; Takada Y
    Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis.
    Kim HS; Chang I; Kim JY; Choi KH; Lee MS
    Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
    Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin.
    Ammirante M; Di Giacomo R; De Martino L; Rosati A; Festa M; Gentilella A; Pascale MC; Belisario MA; Leone A; Turco MC; De Feo V
    Cancer Res; 2006 Apr; 66(8):4385-93. PubMed ID: 16618764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
    Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
    Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
    Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
    Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
    Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
    Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
    Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
    Hermisson M; Weller M
    Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
    Izeradjene K; Douglas L; Delaney AB; Houghton JA
    Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
    Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME
    Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.